Julia Lainster

Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates

Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent

Imagine a hidden ecosystem within the human body, teeming with trillions of microorganisms that quietly shape health, digestion, and even mood. This delicate gut microbiome, a cornerstone of well-being, faces an invisible yet pervasive danger: chemical pollutants. From pesticides on produce to

The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force

For thousands living with spinal muscular atrophy who aged out of early approvals, the FDA’s greenlight of an intrathecal gene therapy redrew the treatment map and challenged long‑held limits. The authorization of Itvisma, an intrathecal formulation of onasemnogene abeparvovec for patients two

After first-line therapy fails in advanced biliary cancer, the next decision can stretch between hope for extra months and fear of heavy toxicity, a fraught balance that now places FOLFIRINOX squarely under the spotlight. Clinics see this crossroads every week: a patient who just progressed on

The scale of diabetic eye screening would swamp any manual system left to grow unchecked, with more than four million people eligible in England and tens of millions of images flowing through a pipeline that still leans on multiple human graders per case to keep patients safe and services moving.

Julia Lainster sits down with Ivan Kairatov, a seasoned biopharma leader with deep experience in oncology R&D, to unpack the latest data from OptiTROP-Lung05 and what it could mean for first-line NSCLC. They explore how a TROP2-directed antibody-drug conjugate combined with an immune checkpoint

Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of

Wrist fractures, specifically distal radius fractures, rank among the most frequent orthopedic injuries, particularly impacting older adults who are prone to falls or trauma. These injuries often disrupt daily routines with persistent pain and limited mobility, making recovery a frustratingly slow